Guangdong Second Provincial General Hospital
Clinical trials sponsored by Guangdong Second Provincial General Hospital, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New combo shows promise for Tough-to-Treat leukemia Results expected Dec 2026 (estimated)
- Could a drug help AML patients fight Chemo-Related anemia? Results expected Dec 2026 (estimated)
- New combo aims to keep leukemia away after remission Results expected Apr 2027 (estimated)
- Can a new drug trio overcome venetoclax resistance in leukemia? Results expected Sep 2027 (estimated)
-
Can an HDAC inhibitor wipe out residual leukemia cells?
Disease control OngoingResearchers are studying whether the drug chidamide can help keep high-risk acute myeloid leukemia (AML) in remission when used as maintenance therapy. The trial enrolls adults with specific genetic features and measurable residual disease who are not receiving a stem cell transp…
Sponsor: Guangdong Second Provincial General Hospital • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can a new drug trio overcome venetoclax resistance in leukemia?
Disease control By invitation onlyResearchers are testing whether a combination of homoharringtonine, lisaftoclax, and azacitidine can help adults with acute myeloid leukemia (AML) whose disease stopped responding to venetoclax-based treatment. The trial plans to enroll 73 participants and give them the three dru…
Phase 2 • Sponsor: Guangdong Second Provincial General Hospital • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New combo aims to keep leukemia away after remission
Disease control By invitation onlyThis study tests whether adding venetoclax to standard chemotherapy (cytarabine) can help adults with acute myeloid leukemia (AML) stay in remission longer. About 232 participants who are already in remission will receive either the combination or chemo alone. The main goal is to…
Phase 2/3 • Sponsor: Guangdong Second Provincial General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New combo shows promise for Tough-to-Treat leukemia
Disease control By invitation onlyThis study tests a combination of three drugs (homoharringtonine, venetoclax, and azacitidine) in 40 adults newly diagnosed with a rare and aggressive leukemia called mixed-phenotype acute leukemia (MPAL). The goal is to see if this drug combo can safely help more patients achiev…
Phase 2 • Sponsor: Guangdong Second Provincial General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC